June 27, 2023 Experience Noile-Immune Biotech ¥3.1 billion global IPO The shares are listed on the Tokyo Stock Exchange
June 5, 2023 Experience Oculis Holding $40.25 million debut equity offering The shares are listed on the Nasdaq Global Market
May 17, 2023 Experience Forbion European Acquisition combination with enGene We are advising Forbion European Acquisition on its de-SPAC transaction
May 12, 2023 Experience GSK exclusive licensing agreement with Scynexis We advised GSK on the transaction
May 9, 2023 Experience ACELYRIN $621 million IPO The stock is listed on the Nasdaq Global Select Market
May 8, 2023 Experience Kenvue $4.37 billion IPO The carve-out of the former Johnson & Johnson consumer health business is the largest U.S. IPO since November 2021
May 3, 2023 Experience Cellular Biomedicine Group CAR-T collaboration and license agreement with Janssen We are advising Cellular Biomedicine Group on the transaction
March 7, 2023 Experience Atairos acquisition of LifeLabs Learning We are advising Atairos on the transaction
March 3, 2023 Experience European Biotech Acquisition $220 million combination with Oculis We advised European Biotech Acquisition on its de-SPAC transaction
January 19, 2023 Experience Sun Pharmaceutical acquisition of Concert Pharmaceuticals We advised Sun Pharmaceutical on the transaction